Pfizer is adding follow-on biologics to pipeline

04/27/2010 | Wall Street Journal, The

Pfizer is working to boost its biotech business by developing new versions of blockbuster treatments, including formulations of blood cancer drug Rituxan and rheumatoid arthritis medicine Enbrel that require fewer injections. The company is using Trubion Pharmaceuticals' technology to tailor the "bio-betters," some of which are in midstage development.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Accreditation
Meridian Health Plan
Detroit, MI
Stop Loss Sales Executive, (Southern Region)
Indigo Insurance Services
Multiple Locations, SL_Multiple Locations
Chief Executive Officer
Center for Improving Value in Healthcare
Denver, CO
Quality Program Manager II, State Programs
Tufts Health Plan
Watertown, MA
Senior director risk adjustor and coding doc
Novant Health
Charlotte, NC